These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19360352)

  • 21. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Much ado about Nutlin.
    Teoh NC
    J Gastroenterol Hepatol; 2011 Feb; 26(2):213-5. PubMed ID: 21261708
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
    Park EJ; Choi KS; Yoo YH; Kwon TK
    Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
    Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
    Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
    Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma.
    Shi Y; Takenobu H; Kurata K; Yamaguchi Y; Yanagisawa R; Ohira M; Koike K; Nakagawara A; Jiang LL; Kamijo T
    Eur J Cancer; 2010 Aug; 46(12):2324-34. PubMed ID: 20591651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
    BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD; Beck JF; Sonnemann J
    Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
    Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.